article Open AccessTop 1% cited

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut · 2012 · Vol. 61(12) · pp. 1693–1700

Wolfgang Hueber✉(Novartis (Switzerland))Bruce E. Sands(Mount Sinai Medical Center)Steve Lewitzky(Novartis (United States))Marc Vandemeulebroecke(Novartis (Switzerland))Walter Reinisch(Medical University of Vienna)Peter Higgins(University of Michigan)Jan Wehkamp(Robert Bosch Hospital)Brian G. Feagan(Western University)Michael Yao(National Institutes of Health)Marek KarczewskiJacek KarczewskiNicole Pezous(Novartis (Switzerland))Stephan Bek(Novartis (Switzerland))Gerard Bruin(Novartis (Switzerland))Bjoern Mellgard(Novartis (Switzerland))C Berger(Novartis (Switzerland))Marco Londei(Genomics Institute of the Novartis Research Foundation)Arthur P. Bertolino(Novartis (Switzerland))Gervais Tougas(Novartis (Switzerland))Simon Travis(University of Oxford)for the Secukinumab in Crohn's Disease Study Group

View via DOI Publisher page

Abstract

This trial was registered at ClinicalTrial.gov with the number NCT01009281.

Inflammatory Bowel Disease Immunodeficiency and Autoimmune Disorders Autoimmune Bullous Skin DiseasesSecukinumabPlaceboMedicineInternal medicineClinical endpointAdverse effectCrohn's diseaseConfidence intervalRandomized controlled trialGastroenterology

MeSH terms

AdolescentAdultAgedAnti-Inflammatory AgentsAntibodies, MonoclonalBayes TheoremCrohn DiseaseDouble-Blind MethodDrug Administration ScheduleFemaleGenetic MarkersHumansInfusions, IntravenousMaleMiddle Aged